NCT02503423: Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: cIAP, NF1/2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients with activation or amplification of the NF pathway or c-IAP1/2 will be eligible for the dose expansion (Phase 2)
Exclusions: Patients with known untreated & unstable brain metastases
https://ClinicalTrials.gov/show/NCT02503423

Comments are closed.

Up ↑